Maze Therapeutics, Inc. Price & Performance (MAZE)

Maze Therapeutics has received positive ratings from multiple firms, including Guggenheim, Cowen, and JPMorgan, following its recent IPO. Analysts emphasize the potential of lead drug MZE829, targeting APOL1 kidney disease, with a market opportunity of up to $15 billion. The stock, trading near its 52-week low, is seen as undervalued given its promising pipeline.123

Maze Therapeutics' IPO priced at $16 per share has drawn significant interest, with shares currently trading at $10.82. Analysts have set price targets ranging from $19 to $30, citing the company's proprietary Compass platform and its potential to address unmet medical needs in kidney and metabolic diseases.124

Maze Therapeutics' drug candidates, MZE829 and MZE782, are driving analyst optimism. MZE829, an APOL1 inhibitor, targets over one million U.S. kidney disease patients, while MZE782 offers potential in chronic kidney disease. Analysts project peak sales of $2.5 billion and $1.8 billion, respectively, underscoring the company's growth potential.243